Sugi Predict

Sugi Predict / Compounds / SCHEMBL486222

SCHEMBL486222

SCHEMBL486222

O=S(=O)(Cl)c1cccc(I)c1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.52
▸ HSD17B10 Q99714 2/20 0.52
▸ TDP1 Q9NUW8 2/20 0.52
▸ CA1 P00915 4/20 0.39
▸ CA2 P00918 4/20 0.39
▸ LMNA P02545 2/20 0.36
▸ PMP22 Q01453 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ CA12 O43570 3/20 0.36
▸ CA9 Q16790 3/20 0.36
▸ FAAH O00519 1/20 0.35
▸ MGLL Q99685 1/20 0.35
▸ CA4 P22748 1/20 0.34
▸ CA14 Q9ULX7 1/20 0.34
▸ HTR6 P50406 3/20 0.34
▸ HTR2C P28335 1/20 0.34
▸ TSHR P16473 1/20 0.33
▸ IDO1 P14902 1/20 0.32
▸ APOBEC3G Q9HC16 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27608427 0.92 ALDH1A1 (0.45) ALDH1A1HSD17B10TDP1CA1CA2
SCHEMBL56599 0.83 ALDH1A1 (0.65) ALDH1A1HSD17B10TDP1CA1CA2
SCHEMBL30084552 0.81 LMNA (0.54) ALDH1A1CA1CA2LMNAPMP22
SCHEMBL3677379 0.81 LMNA (0.54) ALDH1A1CA1CA2LMNAPMP22
SCHEMBL27719531 0.80 LMNA (0.40) ALDH1A1HSD17B10TDP1CA1CA2
SCHEMBL8960195 0.79 CA1 (0.41) ALDH1A1HSD17B10TDP1CA1CA2
SCHEMBL30628286 0.77 ALDH1A1 (0.42) ALDH1A1HSD17B10CA1CA2SMN1; SMN2
SCHEMBL3919478 0.77 CA2 (0.70) CA1CA2LMNACA12CA9
SCHEMBL3667501 0.77 ALDH1A1 (0.42) ALDH1A1HSD17B10CA1CA2SMN1; SMN2
SCHEMBL19122490 0.77 CA2 (0.39) ALDH1A1HSD17B10TDP1CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119425423-A Positively charged composite membrane and preparation method and application thereof 中国石油化工股份有限公司 2025-02-14 — — CN claimed
CN-119425423-A Positively charged composite membrane and preparation method and application thereof 中国石油化工股份有限公司 2025-02-14 — — CN disclosed
CN-111821503-B Radiopaque high-efficiency drug-loaded embolism microsphere and preparation and application thereof 苏州恒瑞宏远医疗科技有限公司 2022-07-12 — — CN disclosed
CN-111821503-A Radiopaque high-efficiency drug-loaded embolism microsphere and preparation and application thereof 苏州恒瑞宏远医疗科技有限公司 2020-10-27 — — CN disclosed
WO-2019181646-A1 MACROMOLECULAR COMPOUND, ORGANIC SEMICONDUCTOR MATERIAL INCLUDING MACROMOLECULAR COMPOUND, AND ORGANIC ELECTRONIC DEVICE INCLUDING ORGANIC SEMICONDUCTOR MATERIAL 国立大学法人大阪大学 2019-09-26 — — WO disclosed
WO-2019181645-A1 COMPOUND, PRECURSOR TO COMPOUND, ORGANIC SEMICONDUCTOR MATERIAL INCLUDING COMPOUND, AND ORGANIC ELECTRONIC DEVICE INCLUDING ORGANIC SEMICONDUCTOR MATERIAL 国立大学法人大阪大学 2019-09-26 — — WO disclosed
EP-3241823-B1 PYRROLE AMIDE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF HITGEN LTD (CN) 2019-04-17 — — EP disclosed
US-20170049904-A1 POLYALKYLENE POLYMER COMPOUNDS AND USES THEREOF BIOGEN MA INC. (US) 2017-02-23 — — US disclosed
EP-1476181-B1 POLYALKYLENE POLYMER COMPOUNDS AND USES THEREOF BIOGEN MA INC (US) 2016-03-23 — — EP disclosed
US-20150246097-A9 Polyalkylene Polymer Compounds and Uses Thereof BIOGEN IDEC MA INC. (US) 2015-09-03 — — US disclosed
EP-1194428-A1 HETEROARYL PROTEASE INHIBITORS AND DIAGNOSTIC IMAGING AGENTS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2002-04-10 — — EP disclosed
WO-2001004117-A1 HETEROARYL PROTEASE INHIBITORS AND DIAGNOSTIC IMAGING AGENTS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2001-01-18 — — WO disclosed
EP-0613468-B1 Substituted salicylic acids for the treatment of autoimmune diseases PHARMACIA & UPJOHN AB (SE) 2000-07-12 — — EP disclosed
CN-1042631-C Novel substituted salicylic acids KABI PHARMACIA AB (SE) 1999-03-24 — — CN disclosed
US-5556855-A TREATMENT OF AUTOIMMUNE DISEASES PHARMACIA AB (SE) 1996-09-17 — — US disclosed
US-5403930-A Chemical intermediate for drugs used in autoimmune diseases PHARMACIA AB (SE) 1995-04-04 — — US disclosed
EP-0613468-A1 NOVEL SUBSTITUTED SALICYCLIC ACIDS Pharmacia & Upjohn Aktiebolag (SE) 1994-09-07 — — EP disclosed
CN-1088918-A The salicylic acid compounds of new replacement KABI PHARMACIA AB (SE) 1994-07-06 — — CN disclosed
US-5302718-A Used for treating autoimmune diseases KABI PHARMACIA AB (SE) 1994-04-12 — — US disclosed
WO-1993010094-A1 NOVEL SUBSTITUTED SALICYCLIC ACIDS KABI PHARMACIA AB (SE) 1993-05-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150246097-A9 Polyalkylene Polymer Compounds and Uses Thereof HAVCR2, TLR3, CCR8 ALDH1A1 1052/4885HSD17B10 707/4885TDP1 3972/4885
US-20170049904-A1 POLYALKYLENE POLYMER COMPOUNDS AND USES THEREOF HAVCR2, TLR3, CCR8 ALDH1A1 1052/4885HSD17B10 707/4885TDP1 3972/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.